Whitehawk Therapeutics (WHWK) Return on Capital Employed (2011 - 2026)
Whitehawk Therapeutics (WHWK) reported Return on Capital Employed of 9.87% for Q1 2026, up 3529.0% year-over-year from 0.27% in Q1 2025, and down 229.49% quarter-over-quarter from 3.0% in Q4 2025.
Whitehawk Therapeutics (WHWK) Return on Capital Employed (2011 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 16 years of Return on Capital Employed data on file, last reported at 9.87% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 9.87%, up 3529.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9.87% (up 3529.0% YoY), and the FY2025 annual result was 4.5%, up 7552.0% from the prior year.
- Return on Capital Employed fell to 9.87% in Q1 2026 per WHWK's latest filing, from 3.0% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 3.0% in Q4 2025 and troughed at 110.71% in Q4 2024.
- A 5-year average of 59.68% and a median of 55.79% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed plunged 12641 bps in 2022, then jumped 10771 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 36.8% in 2022, then plunged by 78 bps to 65.6% in 2023, then slumped by 69 bps to 110.71% in 2024, then surged by 97 bps to 3.0% in 2025, then tumbled by 229 bps to 9.87% in 2026.
- Business Quant data shows WHWK's Return on Capital Employed at 9.87% in Q1 2026, 3.0% in Q4 2025, and 66.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | -9.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.87% |
| Dec 31, 2025 | -3.00% |
| Sep 30, 2025 | -66.11% |
| Jun 30, 2025 | -51.51% |
| Mar 31, 2025 | -45.15% |
| Dec 31, 2024 | -110.71% |
| Sep 30, 2024 | -85.07% |
| Jun 30, 2024 | -83.92% |
| Mar 31, 2024 | -73.25% |
| Dec 31, 2023 | -65.60% |
| Sep 30, 2023 | -55.79% |
| Jun 30, 2023 | -45.20% |
| Mar 31, 2023 | -41.14% |
| Dec 31, 2022 | -36.80% |
| Sep 30, 2022 | -44.02% |
| Jun 30, 2022 | -110.21% |
| Mar 31, 2022 | -87.26% |
| Dec 31, 2021 | -75.11% |
| Sep 30, 2021 | -94.91% |
| Jun 30, 2021 | -5.99% |